FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI
In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics
Search Committee Finishes Job, Submits Choices To Califano
New ACS Grants to Fund ‘Critical, Urgent’ Research
Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes
UICC Announces Grant Programs to Continue
NCI Goofs On Contract Notice, Won’t Change Improper Deadline
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists” - ASCO & The Conquer Cancer Foundation announce merit awards
- CBER Director Vinay Prasad dared to “say no to drugs”









